Jornal Vascular Brasileiro
https://jvascbras.org/article/doi/10.1590/jvb.2014.045
Jornal Vascular Brasileiro
Original Article

Biomarkers of inflammation may be of use for identification of more severe peripheral arterial occlusive disease

Biomarcadores inflamatórios circulantes podem ser úteis para identificar doença arterial obstrutiva periférica mais grave

Luciana Garofolo; Sandra Roberta Gouvea Ferreira; Fausto Miranda Junior

Downloads: 1
Views: 787

Abstract

Background:Atherosclerosis is a multifactorial disease with an inflammatory pathophysiological basis. Cytokines released during the atherosclerotic process induce production of C-reactive protein (CRP) in the liver, which is an important marker of inflammation.Objective:We tested whether inflammatory biomarkers were associated with deterioration of peripheral arterial occlusive disease (PAOD) in a population at high cardiovascular risk.Methods:1,330 subjects ≥30 years of age underwent clinical and laboratory examinations as part of a population-based study of the prevalence of diabetes. PAOD was defined as an ankle-brachial index (ABI) ≤0.90. After application of exclusion criteria, the sample comprised 1,038 subjects. Traditional risk factors, CRP and interleukin 6 (IL-6) were also compared across three ABI categories (≤0.70; 0.71-0.90; ≥0.90). Mean values for these variables were compared by presence/absence of DAOP (Student's t test) and by ABI categories (ANOVA). Poisson regression and logistic regression models were used to test for associations between risk factors and DAOP and between risk factors and the ABI categories. Pearson's linear correlation coefficients were calculated for the relationship between CRP and IL-6 levels.Results:Mean age was 56.8±12.9 years, 54% of the sample were women and the prevalence of DAOP was 21.0% (95%CI 18.4-24.1). Individuals with ABI ≤0.70 had higher concentrations of CRP-us (2.1 vs. 1.8) and of IL-6 (1.25 vs. 1.17). Concentrations of CRP and IL-6 were only correlated in patients with DAOP, (p=0.004).Conclusions:The finding that CRP and IL-6 levels were only elevated among people with advanced DAOP may suggest that these biomarkers have a role to play as indicators of more severe disease. Prospective studies are needed to test this hypothesis.

Keywords

atherosclerosis, peripheral arterial occlusive disease, biomarkers

Resumo

Contexto:Aterosclerose é doença multifatorial, cuja base fisiopatológica é um processo inflamatório. Estudos são controversos quanto ao papel dos biomarcadores como fatores de risco. A liberação de citoquinas durante aterogênese promove síntese hepática de proteína C-reativa (PCR), importante marcador inflamatório.Objetivo:Avaliamos se biomarcadores inflamatórios estavam associados à deterioração da doença arterial obstrutiva periférica (DAOP), em população de risco cardiovascular.Métodos:Estudo populacional sobre prevalência de diabetes, em que 1.330 indivíduos com ≥30 anos foram submetidos a exames clínico-laboratoriais. Diagnóstico de DAOP foi feito pelo índice tornozelo-braço (ITB) ≤0,90. Após exclusões, 1.038 indivíduos foram analisados. Fatores de risco tradicionais, PCR e interleucina 6 (IL-6) foram comparados também segundo três categorias de ITB (≤0,70; 0,71-0,90; ≥0,90). Valores médios das variáveis foram comparados segundo presença de DAOP (teste t Student) e categorias do ITB (ANOVA). Utilizou-se modelo de Poisson e regressão logística para avaliar associações da DAOP e categorias do ITB com fatores de risco. Estimou-se coeficiente de correlação linear de Pearson para relação entre os valores de PCR e IL-6.Resultados:A idade média foi 56,8±12,9 anos, 54% mulheres e prevalência de DAOP 21,0% (IC95% 18,4-24,1). Indivíduos com ITB ≤0,70 apresentaram maiores valores de PCR-us (2,1 vs. 1,8) e IL-6 (1,25 vs. 1,17. Apenas em portadores de DAOP, valores de PCR e IL-6 mostraram-se correlacionados (p=0,004).Conclusão:O achado de concentrações mais elevadas de PCR e IL-6 apenas em indivíduos com DAOP avançada pode sugerir um papel destes biomarcadores, indicando doença mais grave. Estudos prospectivos são necessários para testar esta hipótese.

Palavras-chave

aterosclerose, doença arterial periférica obstrutiva, biomarcadores

References

Ablij H, Meinders A. C-reactive protein: history and revival. Eur J Intern Med. 2002;13(7):412-22.

Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-72.

Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.

Calabró P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108(16):1930-2.

Sun H, Koike T, Ichikawa T. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005;167(4):1139-48.

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000;148(2):209-14.

Goff Jr DC, Lloyd-Jones DM, Bennett G. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25^sSuppl 2):S49-73.

Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.

Fowers FGR, Rudan D, Rudan I. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;38(9901):1329-40.

Criqui MH, Langer RD, Fronek A. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-6.

Lerario DD, Gimeno SG, Franco LJ, Iunes M, Ferreira SRG. Weight excess and abdominal fat in the metabolic syndrome among Japanese-Brazilians. Rev Saude Publica. 2002;36(1):4-11.

Gimeno SG, Ferreira SR, Franco LJ, Hirai AT, Matsumura L, Moisés RS. Prevalence and 7-year incidence of Type II diabetes mellitus in a Japanese-Brazilian population: an alarming public health problem. Diabetologia. 2002;45(12):1635-8.

Siqueira AFA, Franco LJ, Gimeno SGA, the JBDSG. Macrovascular disease in a Japanese-Brazilian population of high prevalence of metabolic syndrome: associations with classical and non-classical risk factors. Atherosclerosis. 2007;195(1):160-6.

New criteria for 'obesity disease' in Japan. Circ J. 2002;66(11):987-92.

The Asia-Pacific perspective: redefining obesity and its treatment. 2000.

The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. 2004.

Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(^sSuppl. 1):S11-61.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.

Becker MA, Schumacher Jr HR, Wortmann RL. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-61.

Garofolo L, Barros Jr N, Miranda Jr F, D'Almeida V, Cardien LC, Ferreira SR. Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. Eur J Vasc Endovasc Surg. 2007;34(1):23-8.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(1^sSuppl S):S5-67.

McDermott MM, Green D, Greenland P. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003;92(2):194-9.

Ferreira SRG, Almeida-Pittito B. Reflexão sobre a imigração japonesa no Brasil sob o ângulo da adiposidade corporal. Arq Bras Endocrinol Metabol. 2009;53(2):175-82.

Hirsch AT, Criqui MH, Treat-Jacobson D. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-24.

Elhadd T, Robb R, Jung R, Stonebrigde P, Belch J. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Pract Diab Int. 1999;16(6):163-6.

Makdisse M, Pereira AC, Brasil DP. Prevalence and risk factors associated with peripheral arterial disease in the Hearts of Brazil Project. Arq Bras Cardiol. 2008;91(6):370-82.

Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005;112(7):976-83.

Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9.

Sunyer J, Forastiere F, Pekkanen J. Interaction between smoking and the interleukin-6 gene affects systemic levels of inflammatory biomarkers. Nicotine Tob Res. 2009;11(11):1347-53.

Signorelli SS, Mazzarino MC, Di Pino L. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med. 2003;8(1):15-9.

Danielsson P, Truedsson L, Eriksson K-F, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med. 2005;10(3):191-8.

Chapman CM, Beilby JP, McQuillan BM, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke. 2004;35(7):1619-24.

Wang TJ, Nam BH, Wilson PW. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22(10):1662-7.

Luc G, Bard JM, Juhan-Vague I. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol. 2003;23(7):1255-61.

Su D, Li Z, Li X. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm. 2013;2013:726178.

Biasucci LM, Liuzzo G, Fantuzzi G. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99(16):2079-84.

Ikeda U. Inf lammation and coronary artery disease. Curr Vasc Pharmacol. 2003;1(1):65-70.

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5ddd80660e882507361da3e9 jvb Articles

J Vasc Bras

Share this page
Page Sections